UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
SCHEDULE 13D
Under the Securities Exchange Act of 1934
(Amendment No. ___)*
AETHLON MEDICAL, INC.
(Name of Issuer)
Common Stock
(Title of Class of Securities)
00808Y09
(CUSIP Number)
Christian J. Hoffmann, III
QUARLES & BRADY STREICH LANG LLP
Renaissance One
Two N. Central Avenue
Phoenix, Arizona 85004
(602) 229-5200
(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)
October 7, 2005
(Date of Event Which Requires Filing of this Statement)
If the filing person has previously filed a statement on Schedule 13G to report
the acquisition which is the subject of this Schedule 13D, and is filing this
schedule because of Rule 13d-1(b)(3) or (4), check the following box [ ]
*The remainder of this cover page shall be filled out for a Reporting Person's
initial filing on this form with respect to the subject class of securities, and
for any subsequent amendment containing information which would alter
disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be deemed
to be "filed" for the purpose of Section 18 of the Securities Exchange Act of
1934 ("Act") or otherwise subject to the liabilities of that section of the act
but shall be subject to all other provisions of the Act (however, see the
Notes).
SCHEDULE 13D
CUSIP No. 00808Y09
--------------------------------------------------------------------------------
1 NAME OF REPORTING PERSON AND S.S. OR I.R.S. IDENTIFICATION NO. OF PERSON
Allan S. Bird
--------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP IRS ID #________________
(a) ___
(b) ___
--------------------------------------------------------------------------------
3 SEC USE ONLY
--------------------------------------------------------------------------------
4 SOURCE OF FUNDS PF
--------------------------------------------------------------------------------
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED
PURSUANT TO ITEMS 2(d) or 2(e)
__________
__________
--------------------------------------------------------------------------------
6 CITIZENSHIP OR PLACE OF ORGANIZATION US
--------------------------------------------------------------------------------
7 NUMBER OF SHARES SOLE VOTING POWER 1,750,000*
8 BENEFICIALLY OWNED SHARED VOTING POWER __________
9 BY EACH REPORTING SOLE DISPOSITIVE POWER 1,750,000*
10 PERSON WITH SHARED DISPOSITIVE POWER __________
--------------------------------------------------------------------------------
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY REPORTING PERSON 1,750,000*
--------------------------------------------------------------------------------
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES
CERTAIN SHARES __________
--------------------------------------------------------------------------------
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 8.5%
--------------------------------------------------------------------------------
14 TYPE OF REPORTING PERSON 00
--------------------------------------------------------------------------------
* See Response to Item 5 below.
ITEM 1. SECURITY AND ISSUER
The title of the class of equity security to which this statement relates
is Common Stock, $.001 par value. The Reporting Person owns two Series A
Convertible Notes (the "Notes") with a total principal amount of $175,000 issued
by the Issuer. The Notes are convertible into units (the "Units") at a price of
$.20 per Unit. Each Unit is composed of one share of Common Stock and one Common
Stock Purchase Warrant (the "Warrant") exercisable to purchase one share of
Common Stock at a price of $.20 per share for a term of three years.
The Issuer of the securities is Aethlon Medical, Inc. (the "Issuer"). The
Issuer's principal executive offices are located at 3030 Bunker Hill Street,
Suite 4000, San Diego, CA 92109.
ITEM 2. IDENTITY AND BACKGROUND
(a) The name of the Reporting Person filing this statement is Allan S.
Bird.
(b) The business address of the Reporting Person is 818 W. Brooks Ave., N.
Las Vegas, Nevada 89030.
(c) The Reporting Person has not, during the past five years, been
convicted in a criminal proceeding.
(d) The Reporting Person has not, during the past five years, been a party
to a civil proceeding of a judicial or administrative body of competent
jurisdiction which resulted in a judgment, decree or final order enjoining
future violations of, or prohibiting or mandating activities subject to, federal
or state securities laws or finding any violation with respect to such laws.
(e) The Reporting Person is a citizen of the United States.
ITEM 3. SOURCE AND AMOUNT OF FUNDS OR OTHER CONSIDERATION
The Reporting Person used his personal funds to invest in the Notes.
ITEM 4. PURPOSE OF TRANSACTION
This Schedule 13D is being filed because the Reporting Person acquired a 5%
or greater ownership interest in the Issuer as of October 7, 2005 and an 8.5%
ownership interest as of November 7, 2005 through his purchase of the Notes. The
Reporting Person purchased the Notes and thus the Common Stock underlying the
Notes and Warrants for investment. The Reporting Person may purchase up to an
additional $195,000 principal amount of the Series A Notes at any point until
December 31, 2005.
Except as set forth in this Item 4, the Reporting Person has no plans or
proposals that relate to or would result in any of the actions specified in
clauses (a) through (j) of Item 4 of Schedule 13D.
ITEM 5. INTEREST IN SECURITIES OF THE ISSUER
(a) If the Reporting Person converted the entire principal amount of the
Note into Common stock and exercised the Warrants, he would beneficially own
1,750,000 shares of Common Stock, which would represent 8.5% of the issued and
outstanding Common Stock of the Issuer. The Note and the Warrants contain
provisions that the Reporting Person cannot, at any point, own more than 9.9% of
the issued and outstanding Common Stock of the Issuer. Accordingly, the
Reporting Person may convert the Note or exercise the Warrants only to the
extent that its total beneficial ownership of Common Stock will not exceed 9.9%
after such action.
(b) If the Reporting Person converted his Note and exercised the related
Warrants, he would have the sole power to vote and dispose of 1,750,000 shares.
The Reporting Person will be able to vote the shares of Common Stock underlying
the Notes and Warrants only if he converts the Notes into Common Stock and
exercises the Warrants.
(c) The Reporting Person has effected no transactions in the Common Stock
during the past 60 days for himself and his Affiliates.
(d) No person is known to the Reporting Person to have any right to
receive, or power to direct the receipt of, dividends from or the proceeds from
the sale of any of the securities covered by this statement, except as provided
herein.
ITEM 6. CONTRACTS, ARRANGEMENTS, UNDERSTANDINGS OR RELATIONSHIPS WITH RESPECT TO
SECURITIES OF THE ISSUER
The Reporting Person has no contracts, arrangements, understandings or
relationships required to be reported under this Item 6, except the Notes,
Warrants and a Registration Rights Agreement. The Registration Rights Agreement
obligates the Issuer to file a registration statement with the Securities and
Exchange Commission to register the Common Stock underlying the Notes and
Warrants.
ITEM 7. MATERIALS TO BE FILED AS EXHIBITS
The following are required to be filed as Exhibits in connection with this
Schedule 13D:
(i) Form of Note;
(ii) Form of Warrant; and
(iii) Form of Registration Rights Agreement.
-2-
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete and
correct.
November 23, 2005 By: /s/ Allan S. Bird
Date ------------------------------------
Allan S. Bird
-3-